Infigratinib a Novel, Potent Selective TKI Targeting FGFR Fusions in Different Tumor Types.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 3, p. 26
- By:
- Publication type:
- Article
Works matching IS 21534888 AND DT 2019 AND VI 10 AND IP 3
Results: 21
1
2
Umbralisib Shows Encouraging Results in Relapsed or Refractory Marginal-Zone Lymphoma.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 3, p. 25
- By:
- Publication type:
- Article
3
Call to Action: Greater Focus on Metastatic Cancer Survivors Is Needed.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 3, p. 1
- By:
- Publication type:
- Article
4
T-DM1 Reduces Residual Invasive Disease in Patients with HER2-Positive Breast Cancer After Chemotherapy.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 3, p. 34
- By:
- Publication type:
- Article
5
Personalized Neoadjuvant Immunotherapy Combinations Improve Outcomes in Stage III Melanoma.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 3, p. 33
- By:
- Publication type:
- Article
6
Adding PARP Inhibitor to Immune Checkpoint Blockade Improves Responses in Ovarian Cancer with BRCA Mutations.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 3, p. 32
- By:
- Publication type:
- Article
7
Durvalumab plus Tremelimumab Immunotherapy Combination Extends Survival in Refractory Colorectal Cancer.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 3, p. 31
- By:
- Publication type:
- Article
8
Evolving Immuno-Oncology Strategies in Renal-Cell Carcinoma.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 3, p. 30
- By:
- Publication type:
- Article
9
Can Immunotherapy Work in Ovarian Cancer?
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 3, p. 29
- By:
- Publication type:
- Article
10
First Positive Showing for Mesothelin-Directed CAR T-Cell Therapy in Solid Tumors.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 3, p. 28
- By:
- Publication type:
- Article
11
FDA NEWS.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 3, p. 24
- Publication type:
- Article
12
Osimertinib plus Savolitinib Promising for Advanced Non–Small-Cell Lung Cancer and MET-Driven Resistance.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 3, p. 17
- Publication type:
- Article
13
Gilteritinib a New Standard of Care for Relapsed or Refractory AML with FLT3 Mutation.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 3, p. 15
- By:
- Publication type:
- Article
14
Paradigm Shift: Ibrutinib plus Rituximab Front-Line Therapy for Patients Age 70 or Younger with CLL.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 3, p. 14
- By:
- Publication type:
- Article
15
CAR T-Cell Therapy Augments Response to Ibrutinib in Chronic Lymphocytic Leukemia.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 3, p. 13
- By:
- Publication type:
- Article
16
Revised Risk Categories in NCCN Guideline for Metastatic Renal-Cell Carcinoma Affects Preferred Front-Line Options.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 3, p. 12
- By:
- Publication type:
- Article
17
Updated NCCN Guideline Strongly Recommends Germline Testing for All Patients with Pancreatic Cancer.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 3, p. 11
- By:
- Publication type:
- Article
18
New Targeted Therapies for Metastatic Colorectal Cancer Recommended in the Updated NCCN Guideline.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 3, p. 10
- By:
- Publication type:
- Article
19
Assessment of Opioid Misuse and Abuse Should Be Part of Cancer Pain Management.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 3, p. 1
- By:
- Publication type:
- Article
20
High Tumor Mutation Burden Predictive Biomarker for Survival in Metastatic Lung Cancer.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 3, p. 1
- By:
- Publication type:
- Article
21
Expert Panel Discusses Access to CAR T-Cell Therapy.
- Published in:
- 2019
- By:
- Publication type:
- Proceeding